Patents by Inventor Keith McCormack
Keith McCormack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11790324Abstract: In non-limiting examples of the present disclosure, systems, methods and devices for initiating and managing electronic focus sessions are provided. A focus session window may be displayed. The focus session window may comprise a timer pane comprising a focus session duration input element; a task pane comprising an identity of at least one task object created by a task management application; a music pane comprising an identity of at least one music playlist; and/or a daily progress pane that includes a goal display element indicating a duration of time spent in focus sessions for a current day. An indication to initiate a focus session may be received. The initiating may comprise causing a timer for the duration of time to be initiated and displayed in the timer pane and causing one of the music playlists to be automatically played.Type: GrantFiled: May 26, 2021Date of Patent: October 17, 2023Assignee: MICROSOFT TECHNOLOGY LICENSING, LLCInventors: Liang Chen, Rian Keith McCormack, Herrick Heath Spencer, Eric Hwa-Wei Wong, David Grochocki, Jr., Marcus Henry Perryman
-
Publication number: 20220385753Abstract: In non-limiting examples of the present disclosure, systems, methods and devices for initiating and managing electronic focus sessions are provided. A focus session window may be displayed. The focus session window may comprise a timer pane comprising a focus session duration input element; a task pane comprising an identity of at least one task object created by a task management application; a music pane comprising an identity of at least one music playlist; and/or a daily progress pane that includes a goal display element indicating a duration of time spent in focus sessions for a current day. An indication to initiate a focus session may be received. The initiating may comprise causing a timer for the duration of time to be initiated and displayed in the timer pane and causing one of the music playlists to be automatically played.Type: ApplicationFiled: May 26, 2021Publication date: December 1, 2022Inventors: Liang CHEN, Rian Keith MCCORMACK, Herrick Heath SPENCER, Eric Hwa-Wei WONG, David GROCHOCKI, JR., Marcus Henry PERRYMAN
-
Publication number: 20220383268Abstract: In non-limiting examples of the present disclosure, systems, methods and devices for surfacing interactive focus session insights are provided. An indication to display a focus session insight associated with a user account may be received. An electronic focus session profile associated with the user account may be analyzed. A focus session insight may be caused to be displayed. The focus session insight may include daily or weekly summary data for focus sessions. The daily or weekly summary data may include timeframes when focus sessions were active and task object data for task objects that were associated with active focus sessions during a corresponding day or week. Interactions may be received on display elements of the focus session insights, and task objects may be modified accordingly.Type: ApplicationFiled: May 26, 2021Publication date: December 1, 2022Inventors: Liang CHEN, Rian Keith MCCORMACK, Eric Hwa-Wei WONG
-
Publication number: 20120183493Abstract: The present invention relates to polymers comprising monomer units derived from captopril, and their use in the treatment or prevention of collagen deposition, fibrosis, scars, burns, or unwanted tissue formation. The present invention further relates to processes for the preparation of said polymers and to pharmaceutical compositions and medical products comprising the polymers. Also encompassed by the present invention are polymers comprising monomer units derived from other ACE inhibitors such as zofenopril, alacepril, rentiapril or pivalopril, or from vasopeptidase inhibitors such as fasidotrilat, omapatrilat or ilepatril.Type: ApplicationFiled: May 11, 2010Publication date: July 19, 2012Applicant: PharmaPatents Global Ltd.Inventor: Keith McCormack
-
Patent number: 7402591Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.Type: GrantFiled: October 20, 2005Date of Patent: July 22, 2008Assignee: Reckitt Benckiser Healthcare (UK) LimitedInventors: Christopher Bourne Chapleo, Nicolas Calvert Varey, Keith McCormack
-
Publication number: 20060069113Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.Type: ApplicationFiled: October 20, 2005Publication date: March 30, 2006Inventors: Christopher Chapleo, Nicolas Varey, Keith McCormack
-
Publication number: 20060058333Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.Type: ApplicationFiled: October 20, 2005Publication date: March 16, 2006Inventors: Christopher Chapleo, Nicholas Varey, Keith McCormack
-
Publication number: 20060058332Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.Type: ApplicationFiled: October 20, 2005Publication date: March 16, 2006Inventors: Christopher Chapleo, Nicolas Varey, Keith McCormack
-
Patent number: 6995169Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.Type: GrantFiled: May 14, 2002Date of Patent: February 7, 2006Assignee: Reckitt Benckiser Healthcare (UK) LimitedInventors: Christopher Bourne Chapleo, Nicolas Calvert Varey, Keith McCormack
-
Publication number: 20030004178Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.Type: ApplicationFiled: May 14, 2002Publication date: January 2, 2003Inventors: Christopher Bourne Chapleo, Nicolas Calvert Varey, Keith McCormack